Analyst Joseph Schwartz from Leerink Partners maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) and increased the price target to $44.00 from $42.00. Joseph Schwartz’s rating ...

Edgewise is Not a One-Trick Pony Edgewise Therapeutics has an attractive, if small, pipeline of candidates in early stage 1 ...

Edgewise Therapeutics, Inc. ( (EWTX) ) has released its Q3 earnings. Here is a breakdown of the information Edgewise Therapeutics, Inc.

Edgewise Therapeutics traded as high as $31.34 and last traded at $31.34. 61,766 shares traded hands during trading, a decline of 94% from the average session volume of 962,308 shares. The stock ...

Announced positive top-line data from Phase 1 trial in healthy subjects and Phase 2 CIRRUS-HCM trial in patients with obstructive HCM – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading ...

In other Edgewise Therapeutics news, General Counsel John R. Moore sold 20,922 shares of the company’s stock in a transaction on Monday, September 23rd. The stock was sold at an average price of ...

Analysts Think There's Still Time To Get In On Edgewise Edgewise Therapeutics (NASDAQ: EWTX) is a small-cap pharmaceutical stock that has been all the rage recently. Shares are up 55% in the last ...

Short interest in Edgewise Therapeutics Inc (NASDAQ:EWTX) decreased during the last reporting period, falling from 9.34M to 8.49M. This put 13.29% of the company's publicly available shares short.

--(BUSINESS WIRE)-- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent ...

Announced positive top-line data from Phase 1 trial in healthy subjects and Phase 2 CIRRUS-HCM trial in patients with obstructive HCM – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights. “We ...